BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 20360563)

  • 1. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.
    Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H
    Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of boronic acid based inhibitors of autotaxin.
    Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
    J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a pipemidic acid autotaxin inhibitor.
    Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
    J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
    Zhang R; Wang J; Ma S; Huang Z; Zhang G
    BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
    van Meeteren LA; Ruurs P; Stortelers C; Bouwman P; van Rooijen MA; Pradère JP; Pettit TR; Wakelam MJ; Saulnier-Blache JS; Mummery CL; Moolenaar WH; Jonkers J
    Mol Cell Biol; 2006 Jul; 26(13):5015-22. PubMed ID: 16782887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation and biological activities of the autotaxin-LPA axis.
    van Meeteren LA; Moolenaar WH
    Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions.
    Nakasaki T; Tanaka T; Okudaira S; Hirosawa M; Umemoto E; Otani K; Jin S; Bai Z; Hayasaka H; Fukui Y; Aozasa K; Fujita N; Tsuruo T; Ozono K; Aoki J; Miyasaka M
    Am J Pathol; 2008 Nov; 173(5):1566-76. PubMed ID: 18818380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
    van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
    J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATX-LPA receptor axis in inflammation and cancer.
    Liu S; Murph M; Panupinthu N; Mills GB
    Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATX-LPA axis induces expression of OPN in hepatic cancer cell SMMC7721.
    Zhang R; Zhang Z; Pan X; Huang X; Huang Z; Zhang G
    Anat Rec (Hoboken); 2011 Mar; 294(3):406-11. PubMed ID: 21337710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
    Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
    J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
    Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
    J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
    Federico L; Pamuklar Z; Smyth SS; Morris AJ
    Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
    Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
    J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
    Li S; Wang B; Xu Y; Zhang J
    Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain.
    Inoue M; Ma L; Aoki J; Chun J; Ueda H
    Mol Pain; 2008 Feb; 4():6. PubMed ID: 18261210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
    Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
    ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autotaxin: a protein with two faces.
    Tania M; Khan MA; Zhang H; Li J; Song Y
    Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
    van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH
    Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an activity-based probe for autotaxin.
    Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
    Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.